UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 349

Sortiert nach

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

Oncogene, 2013-03, Vol.32 (11), p.1341-1350

2013

Volltextzugriff (PDF)

The impact of socioeconomic status on access to cancer clinical trials

British journal of cancer, 2014-10, Vol.111 (9), p.1684-1687

2014

Volltextzugriff (PDF)

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

British journal of cancer, 2012-03, Vol.106 (6), p.1100-1106

2012

Volltextzugriff (PDF)

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer

Annals of oncology, 2012-08, Vol.23 (8), p.2094-2102

2012

Volltextzugriff (PDF)

Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer

Current cancer drug targets, 2012-02, Vol.12 (2), p.107

2012

Volltextzugriff (PDF)

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Annals of oncology, 2018-11, Vol.29 (11), p.2214-2222

2018

Volltextzugriff (PDF)

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Annals of oncology, 2019-07, Vol.30 (7), p.1121-1126

2019

Volltextzugriff (PDF)

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Annals of oncology, 2020-08, Vol.31 (8), p.1056-1064

2020

Volltextzugriff (PDF)

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Annals of oncology, 2019-08, Vol.30 (8), p.1321-1328

2019

Volltextzugriff (PDF)

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

Annals of oncology, 2019-03, Vol.30 (3), p.447-455

2019

Volltextzugriff (PDF)

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC

Clinical and translational science, 2022-05, Vol.15 (5), p.1143-1154

2022

Volltextzugriff (PDF)

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Annals of oncology, 2018-03, Vol.29 (3), p.700-706

2018

Volltextzugriff (PDF)

Association of anticoagulant use with clinical outcomes from crizotinib in ALK‐ and ROS1‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001

Cancer medicine (Malden, MA), 2022-12, Vol.11 (23), p.4422-4429

2022

Volltextzugriff (PDF)

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Annals of oncology, 2015-07, Vol.26 (7), p.1421-1427

2015

Volltextzugriff (PDF)

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

Annals of oncology, 2021-05, Vol.32 (5), p.620-630

2021

Volltextzugriff (PDF)

MS06.04 Systemic Therapy for Oligomets: Before, During, or After Local Therapies?

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S262-S262

Camidge, R.

2018

Volltextzugriff (PDF)

A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer

Annals of oncology, 2014-02, Vol.25 (2), p.505-511

2014

Volltextzugriff (PDF)

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Nature medicine, 2022-10, Vol.28 (10), p.2155-2161

2022

Volltextzugriff (PDF)

The epidemiology of self‐poisoning in the UK

British journal of clinical pharmacology, 2003-12, Vol.56 (6), p.613-619

2003

Volltextzugriff (PDF)

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC

NPJ precision oncology, 2021-10, Vol.5 (1), p.91-91, Article 91

2021

Volltextzugriff (PDF)

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer

Investigational new drugs, 2013-02, Vol.31 (1), p.115-125

2013

Volltextzugriff (PDF)

An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii496-viii497

2018

Volltextzugriff (PDF)

Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial

Lung cancer (Amsterdam, Netherlands), 2023-11, Vol.185, p.107376-107376, Article 107376

2023

Volltextzugriff (PDF)

Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S39-S40

2014

Volltextzugriff (PDF)

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Annals of oncology, 2018-10, Vol.29 (10), p.2143-2143

2018

Volltextzugriff (PDF)

1 – 25 von 349

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(347)
Mit Volltextzugriff
(338)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(111)
Science & Technology
(109)
Life Sciences & Biomedicine
(108)
Oncology
(87)
Male
(56)
Lung Neoplasms - Drug Therapy
(52)
Middle Aged
(52)
Female
(47)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(43)
Adult
(41)
Aged
(37)
Lung Neoplasms - Pathology
(36)
Biological And Medical Sciences
(29)
Medical Sciences
(28)
Lung Neoplasms - Genetics
(26)
Tumors
(26)
Lung Cancer
(25)
Carcinoma, Non-Small-Cell Lung - Pathology
(24)
Aged, 80 And Over
(22)
Carcinoma, Non-Small-Cell Lung - Genetics
(22)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

The impact of socioeconomic status on access to cancer clinical trials

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer

Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Association of anticoagulant use with clinical outcomes from crizotinib in ALK‐ and ROS1‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

MS06.04 Systemic Therapy for Oligomets: Before, During, or After Local Therapies?

A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

The epidemiology of self‐poisoning in the UK

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer

An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)

Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial

Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E)

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Suchergebnisse filtern